Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700% [Yahoo! Finance]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Yahoo! Finance
The stock jumped after preliminary 2025 results highlighted roughly 700% growth in Anktiva revenue and a quarterly sales beat. Investors are watching ongoing demand trends and potential label expansions for the therapy. Trading volume reached 70.4 million shares, about 442% above its three-month average of 13 million shares. ImmunityBio IPO'd in 2015 and has fallen 89% since going public. The S&P 500 added 0.27% to finish Thursday at 6,945, while the Nasdaq Composite gained 0.25% to close at 23,530. Within biotechnology, industry peers Incyte closed at $105.24 (-0.67%), and Vertex Pharmaceuticals ended at $438.92 (-2.36%), lagging ImmunityBio's sharp rally. ImmunityBio's fantastic week continued on Thursday, after management released preliminary full-year earnings that exceeded Wall Street's expectations . The company's bladder cancer therapy, Anktiva, helped ImmunityBio's sales jump from $15 million in 2024 to $113 million, according to management's projections. This revenue re
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year [Yahoo! Finance]Yahoo! Finance
- ImmunityBio: Why I Am Upgrading To A Buy For 2026 [Seeking Alpha]Seeking Alpha
- ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-yearBusiness Wire
- Saudi FDA Grants Accelerated Approval to ImmunityBio's ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ [Yahoo! Finance]Yahoo! Finance
- Update: ImmunityBio Gets Approval From Saudi FDA For Non-Muscle Invasive Bladder Cancer Treatment; Shares Rise [Yahoo! Finance]Yahoo! Finance
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 1/15/26 - Form 8-K
- 1/14/26 - Form 8-K
- 1/5/26 - Form 4
- IBRX's page on the SEC website